Azithromycin reduces inflammation in infant cystic fibrosis: trial

The treatment could be considered routinely for early management, Australian researchers say

Azithromycin treatment from diagnosis of cystic fibrosis in newborns can significantly reduce airway inflammation and hospitalisations, a landmark Australian and New Zealand study finds.

Although the macrolide failed to reduce the extent of structural lung damage, the Telethon Kids Institute-led team in Perth say it could still be considered for routine early management of paediatric cases.

In the phase III clinical trial — dubbed COMBAT-CF — 130 infants diagnosed with cystic fibrosis (CF) were